{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:00:01Z","timestamp":1781280001170,"version":"3.54.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40264-026-01656-8","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:52:26Z","timestamp":1772470346000},"page":"775-796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["QT Prolongation Risk of Antibody\u2013Drug Conjugates"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6997-5533","authenticated-orcid":false,"given":"Xu Steven","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Sanghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"8","key":"1656_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/jjco\/hyae054","volume":"54","author":"T Takakura","year":"2024","unstructured":"Takakura T, Shimizu T, Yamamoto N. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy. Jpn J Clin Oncol. 2024;54(8):837\u201346.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1656_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, Li P, Yang T, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1656_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, et al.\u00a0Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.","journal-title":"Signal Transduct Target Ther"},{"key":"1656_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaf004","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Lu J, Zhang C, et al.\u00a0Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors. Antibody Therapeutics 2025;2(8):124-44.\u00a0https:\/\/doi.org\/10.1093\/abt\/tbaf004.","journal-title":"Antibody Ther"},{"issue":"1","key":"1656_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, et al.\u00a0Antibody\u2013drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3\u201319.","journal-title":"Mol Cancer Res"},{"key":"1656_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar A, Sunildutt NP, Ahmed F, et al.\u00a0A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother. 2023;161:114408.","journal-title":"Biomed Pharmacother"},{"issue":"15","key":"1656_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153886","volume":"15","author":"P Gogia","year":"2023","unstructured":"Gogia P, Ashraf H, Bhasin S, et al.\u00a0Antibody\u2013drug conjugates: a review of approved drugs and their clinical level of evidence. Cancers. 2023;15(15):3886.","journal-title":"Cancers"},{"issue":"1","key":"1656_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00338-9","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman N, Yap TA, Heymach JV, et al.\u00a0Antibody-drug conjugates in lung cancer: dawn of a new era? NPJ Precis Oncol. 2023;7(1):5.","journal-title":"NPJ Precis Oncol"},{"key":"1656_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, Li M, Li Y, et al.\u00a0A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers. Mol Cancer. 2024;23:62.","journal-title":"Mol Cancer"},{"key":"1656_CR10","unstructured":"Besponsa (inotuzumab\u00a0ozogamicin) [package insert], in prescribing information. New\u00a0York (NY): Pfizer\u00a0Inc.; 2024."},{"key":"1656_CR11","unstructured":"Trodelvy (sacituzumab\u00a0govitecan\u2011hziy) [package insert], in prescribing information. Foster\u00a0City (CA): Gilead\u00a0Sciences,\u00a0Inc.; 2021."},{"issue":"12","key":"1656_CR12","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1185\/03007995.2013.840568","volume":"29","author":"KE Trinkley","year":"2013","unstructured":"Trinkley KE, Page RL, Lien H, et al.\u00a0QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719\u201326.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1656_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-025-09985-4","volume":"52","author":"Y Ji","year":"2025","unstructured":"Ji Y, Johannesen L, Garnett C. FDA\u2019s insights: implementing new strategies for evaluating drug-induced QTc prolongation. J Pharmacokinet Pharmacodyn. 2025;52(4):37.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1656_CR14","unstructured":"European Medicines Agency. ICH guideline E14\/S7B: clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential\u2014questions and answers\u2014[online] Sept 5. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-e14s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-questions-and-answers-step-5_en.pdf. Accessed 10 Feb 2026."},{"issue":"1","key":"1656_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","volume":"187","author":"JP Valentin","year":"2022","unstructured":"Valentin JP, Hoffmann P, Ortemann-Renon C, et al.\u00a0The challenges of predicting drug-induced QTc prolongation in humans. Toxicol Sci. 2022;187(1):3\u201324.","journal-title":"Toxicol Sci"},{"key":"1656_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2023.107265","volume":"121","author":"HM Vargas","year":"2023","unstructured":"Vargas HM, Rossman EI, Wisialowski TA, et al.\u00a0Improving the in vivo QTc assay: the value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute. J Pharmacol Toxicol Methods. 2023;121:107265.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"1656_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061324","volume":"20","author":"RM Lester","year":"2019","unstructured":"Lester RM, Paglialunga S, Johnson IA. QT assessment in early drug development: the long and the short of it. Int J Mol Sci. 2019;20(6):1324.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1656_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cpt.2029","volume":"109","author":"HM Vargas","year":"2021","unstructured":"Vargas HM, Rolf MG, Wisialowski TA, et al.\u00a0Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: a pharma industry perspective. Clin Pharmacol Ther. 2021;109(2):310\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"1149","key":"1656_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","volume":"97","author":"R Khatib","year":"2021","unstructured":"Khatib R, Sabir FR, Omari C, et al.\u00a0Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452\u20138.","journal-title":"Postgrad Med J"},{"key":"1656_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40261-016-0460-5","volume":"37","author":"R Cuni","year":"2017","unstructured":"Cuni R, Parrini I, Asteggiano R, et al.\u00a0Targeted cancer therapies and QT interval prolongation: unveiling the mechanisms underlying arrhythmic complications and the need for risk stratification strategies. Clin Drug Investig. 2017;37:121\u201334.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1656_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cvr\/cvz013","volume":"115","author":"DM Roden","year":"2019","unstructured":"Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895\u2013903.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"1656_CR22","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, et al.\u00a0The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 2024;14(11):2089\u2013108.","journal-title":"Cancer Discov"},{"key":"1656_CR23","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/212178","volume":"2012","author":"EM Kallergis","year":"2012","unstructured":"Kallergis EM, Goudis CA, Simantirakis EN, et al.\u00a0Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Sci World J. 2012;2012:212178.","journal-title":"Sci World J"},{"issue":"39","key":"1656_CR24","doi-asserted-by":"publisher","first-page":"25738","DOI":"10.18632\/oncotarget.25008","volume":"9","author":"J Duan","year":"2018","unstructured":"Duan J, Tao J, Zhai M, et al.\u00a0Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738.","journal-title":"Oncotarget"},{"issue":"8","key":"1656_CR25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.12968\/denu.2005.32.8.472","volume":"32","author":"MF Ahmed","year":"2005","unstructured":"Ahmed MF, Elseed AI. The medical management and dental implications of long QT syndrome. Dent Update. 2005;32(8):472\u20134.","journal-title":"Dent Update"},{"issue":"8 Pt 2","key":"1656_CR26","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/j.1540-8159.1997.tb03626.x","volume":"20","author":"SG Priori","year":"1997","unstructured":"Priori SG, Napolitano C, Paganini V, et al.\u00a0Molecular biology of the long QT syndrome: impact on management. Pacing Clin Electrophysiol. 1997;20(8 Pt 2):2052\u20137.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"1656_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.vascn.2013.03.005","volume":"68","author":"D Rampe","year":"2013","unstructured":"Rampe D, Brown AM. A history of the role of the hERG channel in cardiac risk assessment. J Pharmacol Toxicol Methods. 2013;68(1):13\u201322.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"4","key":"1656_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1574884713666180223123947","volume":"12","author":"CV Etchegoyen","year":"2017","unstructured":"Etchegoyen CV, Keller GA, Mrad S, et al.\u00a0Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol. 2017;12(4):210\u201322.","journal-title":"Curr Clin Pharmacol"},{"issue":"10200","key":"1656_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793\u2013804.","journal-title":"Lancet"},{"key":"1656_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102922","author":"A G\u00e9raud","year":"2025","unstructured":"G\u00e9raud A, Gougis P, de Nonneville A, et al.\u00a0Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand? Cancer Treat Rev. 2025. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102922.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1656_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/antib10020020","volume":"10","author":"I Mahmood","year":"2021","unstructured":"Mahmood I. Clinical pharmacology of antibody-drug conjugates. Antibodies. 2021;10(2):20.","journal-title":"Antibodies"},{"issue":"8","key":"1656_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/00498254.2024.2351044","volume":"54","author":"MZ Liao","year":"2024","unstructured":"Liao MZ, Leipold DD, Chen SC, et al.\u00a0Translational PK\/PD framework for antibody-drug conjugates to inform drug discovery and development. Xenobiotica. 2024;54(8):543\u201351.","journal-title":"Xenobiotica"},{"issue":"5","key":"1656_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40262-017-0619-0","volume":"57","author":"WD Hedrich","year":"2018","unstructured":"Hedrich WD, Fandy TE, Ashour HM, et al.\u00a0Antibody-drug conjugates: pharmacokinetic\/pharmacodynamic modeling, preclinical characterization, and clinical development. Clin Pharmacokinet. 2018;57(5):687\u2013703.","journal-title":"Clin Pharmacokinet"},{"key":"1656_CR34","unstructured":"US Food and Drug Administration. Clinical pharmacology considerations for antibody-drug conjugates: guidance for industry. Silver Spring (MD): Center for Drug Evaluation and Research; 2024."},{"issue":"7","key":"1656_CR35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40264-021-01069-9","volume":"44","author":"FA Lievano","year":"2021","unstructured":"Lievano FA, Scarazzini LJ, Tyczynski JE, et al. Risk minimization of antibody\u2013drug conjugates in oncology: a review. Drug Saf. 2021;44(7):733\u201342.","journal-title":"Drug Saf"},{"issue":"1","key":"1656_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, et al.\u00a0Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3\u201319.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1656_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.vascn.2013.05.004","volume":"69","author":"H Holzgrefe","year":"2014","unstructured":"Holzgrefe H, Ferber G, Champeroux P, et al. Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium. J Pharmacol Toxicol Methods. 2014;69(1):61\u2013101.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"11","key":"1656_CR38","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1007\/s11095-015-1742-y","volume":"32","author":"JA Lansita","year":"2015","unstructured":"Lansita JA, Burke JM, Apgar JF, et al.\u00a0An introduction to the regulatory and nonclinical aspects of the nonclinical development of antibody drug conjugates. Pharm Res. 2015;32(11):3584\u201392.","journal-title":"Pharm Res"},{"issue":"4","key":"1656_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10928-025-09988-1","volume":"52","author":"SD Shah","year":"2025","unstructured":"Shah SD, Jewell RC, Ferron-Brady G, et al.\u00a0Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology. J Pharmacokinet Pharmacodyn. 2025;52(4):44.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"1656_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2015.34","volume":"15","author":"G Gintant","year":"2016","unstructured":"Gintant G, Sager PT, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15(7):457\u201371.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1656_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4161\/mabs.1.1.7377","volume":"1","author":"CM Lynch","year":"2009","unstructured":"Lynch CM, Hart BW, Grewal IS. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. MAbs. 2009;1(1):2\u201311.","journal-title":"MAbs"},{"key":"1656_CR42","unstructured":"US Food and Drug Administration. New approaches for an integrated nonclinical-clinical QT\/proarrhythmic risk assessment [online]. 2020. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/new-approaches-integrated-nonclinical-clinical-qtproarrhythmic-risk-assessment-10152020. Accessed 10 Feb 2026."},{"issue":"9","key":"1656_CR43","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","volume":"23","author":"EL Giraud","year":"2022","unstructured":"Giraud EL, Ferrier KR, Lankheet NA, et al. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol. 2022;23(9):e406\u201315.","journal-title":"Lancet Oncol"},{"key":"1656_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45:383\u201397.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1656_CR45","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for brentuximab vedotin (Application Number: 125388 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2011."},{"key":"1656_CR46","unstructured":"Adcetris (brentuximab\u00a0vedotin) [package insert], in prescribing information. Bothell (WA): Seagen\u00a0Inc.; 2014."},{"key":"1656_CR47","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for polatuzumab vedotin (Application Number: 761121 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2019."},{"key":"1656_CR48","unstructured":"Polivy (polatuzumab\u00a0vedotin\u2011piiq) [package insert], in prescribing information. South\u00a0San\u00a0Francisco (CA): Genentech\u00a0USA,\u00a0Inc.; 2023."},{"key":"1656_CR49","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for enfortumab vedotin (Application Number: 761137 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2019."},{"issue":"4","key":"1656_CR50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","volume":"63","author":"M Tang","year":"2024","unstructured":"Tang M, Garg A, Bonate PL, et al. Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors. Clin Pharmacokinet. 2024;63(4):423\u201338.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1656_CR51","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. NEngl J Med. 2021;384(12):1125\u201335.","journal-title":"NEngl J Med."},{"key":"1656_CR52","unstructured":"Padcev (enfortumab\u00a0vedotin\u2011ejfv) [package insert], in prescribing information. Northbrook (IL): Astellas\u00a0Pharma\u00a0US,\u00a0Inc.; 2021."},{"key":"1656_CR53","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for tisotumab vedotin (Application Number: 761208 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2021."},{"key":"1656_CR54","unstructured":"Tivdak (tisotumab\u00a0vedotin\u2011tftv) [package insert], in prescribing information. Bothell (WA): Seagen\u00a0Inc.; 2024."},{"key":"1656_CR55","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for telisotuzumab vedotin (Application Number: 761384 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2025."},{"key":"1656_CR56","unstructured":"Emrelis (telisotuzumab\u00a0vedotin\u2011tllv) [package insert], in prescribing information. North\u00a0Chicago (IL): AbbVie\u00a0Inc.; 2025."},{"key":"1656_CR57","unstructured":"US Food and Drug Administration: Blenrep (belantamab mafodotin-blmf) multidiscipline review, in Biologics License Application 761158, Original 1. Silver Spring (MD): Center for Drug Evaluation and Research (CDER); 2020."},{"key":"1656_CR58","unstructured":"Blenrep (belantamab\u00a0mafodotin\u2011blmf) [package insert], in prescribing information. Research\u00a0Triangle\u00a0Park (NC): GlaxoSmithKline; 2020."},{"key":"1656_CR59","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for trastuzumab emtansine (Application Number: 125427 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2013."},{"key":"1656_CR60","unstructured":"Kadcyla (ado\u2011trastuzumab\u00a0emtansine) [package insert], in prescribing information. South\u00a0San\u00a0Francisco (CA): Genentech\u00a0USA,\u00a0Inc.; 2013."},{"key":"1656_CR61","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for mirvetuximab soravtansine (Application Number: 761310 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2022."},{"key":"1656_CR62","unstructured":"Elahere (mirvetuximab\u00a0soravtansine\u2011gynx) [package insert], in prescribing information. Waltham (MA): ImmunoGen,\u00a0Inc.; 2024."},{"key":"1656_CR63","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for sacituzumab govitecan (Application Number: 761115 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2020."},{"key":"1656_CR64","unstructured":"European Medicines Agency. Assessment report: Trodelvy (sacituzumab govitecan). Amsterdam; 2021 Oct 14. Report No.: EMA\/623887\/2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/trodelvy-epar-public-assessment-report_en.pdf. Accessed 9 Feb 2026."},{"key":"1656_CR65","volume-title":"Trodelvy (sacituzumab govitecan-hziy) pharmacokinetics","author":"Gilead Sciences Inc","year":"2025","unstructured":"Gilead Sciences Inc. Trodelvy (sacituzumab govitecan-hziy) pharmacokinetics. Foster City: Gilead Sciences Inc.; 2025."},{"key":"1656_CR66","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for trastuzumab deruxtecan (Application Number: 761139 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2019."},{"key":"1656_CR67","unstructured":"Enhertu (fam\u2011trastuzumab\u202fderuxtecan\u2011nxki) [package insert], in prescribing information. Basking\u00a0Ridge (NJ): Daiichi\u00a0Sankyo,\u00a0Inc.; 2024."},{"key":"1656_CR68","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for datopotamab deruxtecan (Application Number: 761394 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2025."},{"key":"1656_CR69","unstructured":"Datroway (datopotamab\u00a0deruxtecan\u2011dlnk) [package insert], in prescribing information. Basking\u00a0Ridge (NJ): Daiichi\u00a0Sankyo,\u00a0Inc.; 2025."},{"key":"1656_CR70","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for inotuzumab ozogamicin (Application Number: 761040 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2017."},{"key":"1656_CR71","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for gemtuzumab ozogamicin (Application Number: 761060 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2017."},{"key":"1656_CR72","unstructured":"Mylotarg (gemtuzumab ozogamicin) [package insert], in prescribing information. New\u00a0York (NY): Pfizer Inc.; 2017."},{"key":"1656_CR73","unstructured":"US Food and Drug Administration. Multidisciplinary review and evaluation for loncastuximab tesirine (Application Number: 761196 Orig1s000). Silver Spring (MD): Center for Drug Evaluation and Research; 2021."},{"key":"1656_CR74","unstructured":"Zynlonta (loncastuximab\u00a0tesirine\u2011lpyl) [package insert], in prescribing information. Lausanne: ADC\u00a0Therapeutics\u00a0SA; 2021."},{"issue":"10","key":"1656_CR75","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/jcph.1880","volume":"61","author":"B Darpo","year":"2021","unstructured":"Darpo B, Ferber G. The new S7B\/E14 question and answer draft guidance for industry: contents and commentary. J Clin Pharmacol. 2021;61(10):1261\u201373.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1656_CR76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","volume":"159","author":"G Gintant","year":"2017","unstructured":"Pollard CE, Skinner M, Lazic SE, et al. An Analysis of the Relationship Between Preclinical and Clinical QT Interval-Related Data.\u00a0Toxicol Sci. 2017;159(1):94\u2013103.","journal-title":"Toxicol Sci"},{"key":"1656_CR77","unstructured":"Krishna R. Reflections on the new FDA clinical pharmacology guidance for antibody-drug conjugates. Certara Blog. 2022."},{"issue":"2","key":"1656_CR78","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12248-018-0199-4","volume":"20","author":"N Patel","year":"2018","unstructured":"Patel N, Hatley O, Berg A, et al.\u00a0Towards bridging translational gap in cardiotoxicity prediction: an application of progressive cardiac risk assessment strategy in TdP risk assessment of moxifloxacin. AAPS J. 2018;20(3):47.","journal-title":"AAPS J"},{"issue":"11","key":"1656_CR79","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/jcph.2309","volume":"63","author":"B Darpo","year":"2023","unstructured":"Darpo B, Leishman DJ. The new S7B\/E14 Q&a document provides additional opportunities to replace the thorough QT study. J Clin Pharmacol. 2023;63(11):1256\u201374.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1656_CR80","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jcph.2095","volume":"62","author":"B Darpo","year":"2022","unstructured":"Darpo B, Borin M, Ferber G, et al. ECG evaluation as part of the clinical pharmacology strategy in the development of new drugs: a review of current practices and opportunities based on five case studies. J Clin Pharmacol. 2022;62(12):1480\u2013500.","journal-title":"J Clin Pharmacol"},{"key":"1656_CR81","doi-asserted-by":"crossref","unstructured":"Zaro JL, Wang J, Shen WC. Summary and future directions of antibody-drug conjugates, in antibody-drug conjugates. AAPS Advances in the Pharmaceutical Sciences Series. 2025.","DOI":"10.1007\/978-3-031-83005-1"},{"issue":"7","key":"1656_CR82","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","volume":"19","author":"HL Perez","year":"2014","unstructured":"Perez HL, Cardarelli PM, Deshpande S, et al.\u00a0Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19(7):869\u201381.","journal-title":"Drug Discov Today"},{"key":"1656_CR83","unstructured":"Takeda Pharmaceuticals Australia Pty, Ltd. Product information: Adcetris (brentuximab vedotin). Macquarie Park (NSW): Therapeutic Goods Administration (TGA); 2014."},{"key":"1656_CR84","unstructured":"Liao MZ, Deng R, Gibiansky L, et al. Ethnic sensitivity assessment of polatuzumab vedotin pharmacokinetics (PK) in Asian patients with previously untreated diffuse large B-cell lymphoma (DLBCL) from POLARIX, a phase III study. 2022 American College of Clinical Pharmacology (ACCP) Annual Meeting. San Francisco (CA): Genentech, Inc.; 2022."},{"key":"1656_CR85","unstructured":"US\u00a0Food and Drug Administration. QT\u2011IRT consult to BLA\u00a0761121\u00a0(SDN\u00a0001). Silver Spring (MD): US\u00a0Food and Drug Administration; 2019."},{"key":"1656_CR86","volume-title":"Blenrep (belantamab mafodotin): EPAR product information, in European Public Assessment Report (EPAR)","author":"European Medicines Agency","year":"2022","unstructured":"European Medicines Agency. Blenrep (belantamab mafodotin): EPAR product information, in European Public Assessment Report (EPAR). Amsterdam: European Medicines Agency; 2022."},{"issue":"5","key":"1656_CR87","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cpt.2096","volume":"109","author":"O Yin","year":"2021","unstructured":"Yin O, Xiong Y, Endo S, et al.\u00a0Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors. Clin Pharmacol Ther. 2021;109(5):1314\u201325.","journal-title":"Clin Pharmacol Ther"},{"key":"1656_CR88","unstructured":"Daiichi Sankyo Co, Ltd. Datopotamab deruxtecan (Datroway): Japanese package insert, in Pharmaceuticals and Medical Devices Agency (PMDA) New Drug Approval file. Tokyo: PMDA\/Daiichi Sankyo; 2024."},{"issue":"5","key":"1656_CR89","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00280-023-04516-9","volume":"91","author":"P Montesinos","year":"2023","unstructured":"Montesinos P, Kota V, Brandwein J, et al.\u00a0A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed\/refractory CD33-positive acute myeloid leukemia. Cancer Chemother Pharmacol. 2023;91(5):441\u20136.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01656-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01656-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01656-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:03:45Z","timestamp":1781276625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01656-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1656"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01656-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xu Steven Xu, Kinjal Sanghavi, Summer Feng, Sihang Liu, Jeff Barrett, and Manish Gupta are full-time employees of Genmab, Inc. and own Genmab stocks.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study did not involve the generation or analysis of any datasets.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conceptualization and development of the manuscript. XSX, KS, and SL drafted the initial version. All authors reviewed the manuscript and provided critical revisions. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}